Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch’s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch’s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company’s South San Francisco based team has continued to grow as its research has advanced.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $75.3M
Founded date: 2020
Investors 4
| Date | Name | Website |
| 17.03.2023 | Dolby Fami... | dolbyventu... |
| - | Wilson Hil... | wilsonhill... |
| - | Ono Ventur... | onoventure... |
| 26.03.2023 | Upfront Ve... | upfront.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.03.2023 | Series A | $52M | Ono Ventur... |
| 03.10.2022 | - | $23.3M | - |
Mentions in press and media 5
| Date | Title | Description |
| 16.03.2023 | Switch Therapeutics Launches with $52 Million to Advance First-of-its-Kind RNAi Technology | - |
| 14.03.2023 | Switch Therapeutics Raises $52M in Series A Funding | Switch Therapeutics, a South San Francisco, CA-based, preclinical stage biotechnology company, raised $52M in Series A funding. The round was led by Insight Partners and UCB Ventures, with participation from existing investors, including Up... |
| 14.03.2023 | Switch Therapeutics Launches With $52M | SOUTH SAN FRANCISCO, CA, Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use RNA science to treat diseases, today announced its launch following $52 million of financing. >> Click here for mor... |
| - | Ono Venture Investment Invests in Switch Therapeutics. (Switch Therapeutics Launches with $52 Million to Advance First-of-its-Kind RNAi Technology) | - |
| - | Switch Therapeutics | “Switch Therapeutics is a biotech company dedicated to revolutionizing RNA interference (RNAi) therapies with conditionally activated siRNAs (CASi).” |